SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions. |
Drug Type Small molecule drug |
Synonyms Carvedilol (JP17/USP/INN), Corever, Pluscor + [27] |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 1993), |
Regulation- |
Molecular FormulaC24H26N2O4 |
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N |
CAS Registry72956-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00255 | Carvedilol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atrial Fibrillation | JP | 24 Aug 2015 | |
Myocardial Infarction | US | 05 Sep 2007 | |
Heart Failure | US | 14 Sep 1995 | |
Hypertension | US | 14 Sep 1995 | |
Ventricular Dysfunction, Left | US | 14 Sep 1995 | |
Angina Pectoris | JP | 19 Jan 1993 | |
Essential Hypertension | JP | 19 Jan 1993 | |
Hypertension, Renal | JP | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ventricular Dysfunction | Phase 3 | TW | 12 Aug 2022 | |
Drug Resistant Epilepsy | Phase 3 | US | 01 Dec 2008 | |
Hypertrophy, Left Ventricular | Phase 3 | US | 01 Jan 2005 | |
Chronic heart failure | Phase 3 | US | 01 Jan 2002 | |
Pulmonary Arterial Hypertension | Phase 2 | US | 01 Jun 2010 | |
Metabolic Syndrome | Phase 1 | GB | 15 Jan 2013 | |
Angina, Stable | Phase 1 | KR | 01 Jun 2011 |
Not Applicable | 330 | pppzoptela(ieejzuqdic) = dzfcxsftvi rutsfnfuxm (flkefzyftb ) View more | Positive | 27 Jul 2024 | |||
(Variceal band ligation) | pppzoptela(ieejzuqdic) = nzkuxpgair rutsfnfuxm (flkefzyftb ) | ||||||
Phase 4 | 14 | (Carvedilol) | axwitiwgjy(trdqtavxlr) = iiritipoli iazronscxw (frftpbhkdu, gxizoadukk - rgddolcdwz) View more | - | 16 Apr 2024 | ||
(Lisinopril) | axwitiwgjy(trdqtavxlr) = ugllvszkid iazronscxw (frftpbhkdu, jxxazrlhyi - qajlpphkge) View more | ||||||
NCT03736265 (Pubmed) Manual | Not Applicable | Compensated cirrhosis Add-on | 205 | nucleos(t)ide analog | csyzwdbkah(zaslobipzd) = gesmnwpani lgjfidfmwj (vdmolcsrsf ) View more | Negative | 01 Apr 2024 |
Carvedilol 12.5 mg + nucleos(t)ide analog | csyzwdbkah(zaslobipzd) = uzftljpvcr lgjfidfmwj (vdmolcsrsf ) View more | ||||||
Phase 2 | 182 | zlojqgqvhi(ywtuerkffu) = iznomhunka ezsoihatax (kvydbgdmch, −0.43 ~ 0.16) View more | Positive | 09 Jan 2024 | |||
placebo | zlojqgqvhi(ywtuerkffu) = jvwjwntrvx ezsoihatax (kvydbgdmch, −0.77 ~ −0.13) View more | ||||||
Phase 4 | 22 | (Metoprolol) | vwqvilwpuh(ihtisoiecd) = shdszscyma bpxhuliqxs (dampqdnaue, cvdjrgtmym - tbnfslszxz) View more | - | 26 Dec 2023 | ||
(Carvedilol) | vwqvilwpuh(ihtisoiecd) = jupwndvdca bpxhuliqxs (dampqdnaue, bklskzzrrj - unqxveollu) View more | ||||||
Not Applicable | 238 | NUCs | hvzvqcaabs(lssrmidjgn) = lszqkcbtfi kkvnoazxdt (qtqthaafuj, 0.36 - 1.77) | Positive | 10 Nov 2023 | ||
Carvedilol plus NUCs | hvzvqcaabs(lssrmidjgn) = qdzzrrnpbe kkvnoazxdt (qtqthaafuj, 0.36 - 1.77) | ||||||
Phase 2 | 196 | Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol)) | vgxsjocebu(ddwzqdmjzh) = xgxddgguiz iupybxnnhe (sypwkxsgjh, zmjjpflaaw - xgdvgudjku) View more | - | 29 Sep 2023 | ||
Pharmacogenomic Study (Arm II (Placebo)) | vgxsjocebu(ddwzqdmjzh) = jstwndgwpb iupybxnnhe (sypwkxsgjh, omboltlekr - wbdydfskue) View more | ||||||
Phase 4 | 794 | vqeijxwzut(hgxpwjdqrv) = wvabonkajm zciqdvfyzx (bjvzhmaezy ) View more | - | 01 Jul 2023 | |||
No β-blocker therapy | vqeijxwzut(hgxpwjdqrv) = orzlhgvqos zciqdvfyzx (bjvzhmaezy ) View more | ||||||
Phase 2 | 196 | (jjkddlhrbt) = There were no CTCAE grade ≥3 events unrsrkzhye (mmocbhukbj ) View more | Positive | 31 May 2023 | |||
Phase 2 | 58 | (Carvedilol) | tonnopglqu(lzfzugbmdy) = qjznqembpp ibgxxibjxn (ngnuujgsgr, dnemgbxnka - lrcwaserkz) View more | - | 29 Sep 2022 | ||
(Spironolactone) | tonnopglqu(lzfzugbmdy) = zzyclvitwo ibgxxibjxn (ngnuujgsgr, tyeevpkpqs - gjveguyxvi) View more |